Somalia

Population 2018  15 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>39 (25–56)</td>
<td>262 (169–374)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.47 (0.29–0.69)</td>
<td>3.1 (2–4.6)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence*</td>
<td>4 (2.2–6.3)</td>
<td>27 (15–42)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>10 (5.9–15)</td>
<td>67 (40–103)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.23 (0.14–0.34)</td>
<td>1.5 (0.93–2.2)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases 8.7% (6.1–12)
- Previously treated cases 47% (29–65)

TB case notifications, 2018

- % tested with rapid diagnostics at time of diagnosis 18%
- % with known HIV status 90%
- % pulmonary 73%
- % bacteriologically confirmed MDR 61%
- % children aged 0-14 years 22%
- % women 31%
- % men 47%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 42% (30–65)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018 27% (13–45)

TB/HIV care in new and relapse TB patients, 2018

Patients with known HIV status who are HIV-positive

- % on antiretroviral therapy 179 1%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance MDR

- New cases
- Previously treated cases

Laboratory-confirmed cases* MDR/RR-TB: 376, XDR-TB: 3

Patients started on treatment** MDR/RR-TB: 317, XDR-TB: 3

MDR/RR-TB cases tested for resistance to second-line drugs 137

Treatment success rate and cohort size

New and relapse cases registered in 2017 86% 16 627

Previously treated cases, excluding relapse, registered in 2017 76% 142

HIV-positive TB cases registered in 2017 66% 158

MDR/RR-TB cases started on second-line treatment in 2016 79% 244

XDR-TB cases started on second-line treatment in 2016 0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment 20%

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 8.2

Funding source: domestic, 100% international, 0% unfunded

Ranges represent uncertainty intervals

MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2020-01-03